With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

Analysts and investors have been awaiting more proof that Recursion Pharma’s extensive and homegrown datasets can offer drug discovery platforms a speed-to-clinic edge. A $50 million investment the ...

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...